These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32536212)

  • 1. Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?
    Caparica R; De Angelis C; Fêde Â; Werutsky G; de Azambuja E
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):563-573. PubMed ID: 32536212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic chemotherapy for advanced breast cancer patients.
    Cazzaniga ME; Dionisio MR; Riva F
    Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
    Adamo B; Bellet M; Paré L; Pascual T; Vidal M; Pérez Fidalgo JA; Blanch S; Martinez N; Murillo L; Gómez-Pardo P; López-González A; Amillano K; Canes J; Galván P; González-Farré B; González X; Villagrasa P; Ciruelos E; Prat A
    Breast Cancer Res; 2019 Sep; 21(1):108. PubMed ID: 31533777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.
    Petry V; Gagliato DM; Leal AI; Arai RJ; Longo E; Andrade F; Ricci MD; Piato JR; Barroso-Sousa R; Hoff PM; Mano MS
    Braz J Med Biol Res; 2015 May; 48(5):479-85. PubMed ID: 25760024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.
    Mayer EL; Isakoff SJ; Klement G; Downing SR; Chen WY; Hannagan K; Gelman R; Winer EP; Burstein HJ
    Breast Cancer Res Treat; 2012 Nov; 136(1):169-78. PubMed ID: 23001754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
    Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
    Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
    Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.
    Srivastava K; Hu J; Korn C; Savant S; Teichert M; Kapel SS; Jugold M; Besemfelder E; Thomas M; Pasparakis M; Augustin HG
    Cancer Cell; 2014 Dec; 26(6):880-895. PubMed ID: 25490450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of palbociclib for the treatment of advanced breast cancer.
    Degenhardt T; Wuerstlein R; Eggersmann T; Harbeck N
    Expert Opin Drug Saf; 2018 Mar; 17(3):325-330. PubMed ID: 29338448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.
    Montagna E; Vingiani A; Maisonneuve P; Cancello G; Contaldo F; Pruneri G; Colleoni M
    Breast; 2017 Aug; 34():83-88. PubMed ID: 28544923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.
    Cazzaniga ME; Camerini A; Addeo R; Nolè F; Munzone E; Collovà E; Del Conte A; Mencoboni M; Papaldo P; Pasini F; Saracchini S; Bocci G
    Future Oncol; 2016 Feb; 12(3):373-87. PubMed ID: 26584409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics.
    Fares JE; El Tomb P; Khalil LE; Atwani RW; Moukadem HA; Awada A; El Saghir NS
    Cancer Treat Rev; 2020 Sep; 89():102066. PubMed ID: 32769038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
    Li JW; Zuo WJ; Ivanova D; Jia XQ; Lei L; Liu GY
    Breast Cancer Res Treat; 2019 Jan; 173(2):407-415. PubMed ID: 30361875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
    Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
    Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
    El-Arab LR; Swellam M; El Mahdy MM
    J Egypt Natl Canc Inst; 2012 Mar; 24(1):15-22. PubMed ID: 23587228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
    Perroud HA; Alasino CM; Rico MJ; Mainetti LE; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):365-74. PubMed ID: 26721701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.